Outline & Strong point
3.68 million
	In Japan, the number of cancer patients was unknown until now. This marketing report “Japan Cancer Report 2013”has revealed the number of patients for the first time in Japan. 　3.68 million ─ this is the total number of surviving cancer patients*. In fact, the cancer market consists of the total number of surviving patients which amounts to 4 times of 880,000 new-onset patients in 2013. This is the new findings on cancer patients that first came out in Japan. (*：Total number of surviving patients is the total of each year’s surviving patients calculated based on the 5-year or 10-year survival rates.)
Market Scale = Total Number of Surviving Patients
	The total number of surviving patients which indicates how many patients actually exist at the present time, is the only basic data that makes it possible to forecast market scale. As the term implies, the number of new-onset patients presents the number of patients suffering the onset of symptoms during the year in question, and it is impossible to give a comprehensive overview by calculating the market scale based on this figure. The number of patients “who are probably still alive and receiving treatment,” in other words, the total number of surviving patients, makes it possible to forecast the maximum market size for the first time ever. 　Our book provides basic data for identifying numbers of patients targeted for new medicines on a carcinoma-specific, stage-specific and histopathological-specific basis. 　Thus, it is fair to say that calculation of the total number of surviving patients has produced groundbreaking indices that never before existed.
Potential Market
	Calculating the number of patients is based on survival rates. Therefore, high- and-low rates are highly influential on market size. The distinctive examples are lung cancer and breast cancer. In 2013, while the number of new-onset patients of lung and breast cancer are 110,000 and 50,000, the total surviving patients for lung and breast cancer will be 330,000 and 480,000 respectively, with the result that breast cancer has more patients than lung cancer. That is to say, the market size for breast cancer is larger than that of lung cancer. The defining differences of the 5-year or 10-year survival rates are reflected in the market size. Each market size is determined by the total number of surviving patients.
19 cancers
	19 types of cancer are individually dealt with this book and analyzed in detail. The criterion of selecting types of cancer to be dealt with is whether the cancer accounts for over 1% of total deaths of cancer (malignant neoplasm) patients in the Vital Statistics. The 5-year or 10-year survival rates, each year’s survival rates, survival rates by stage, stage distribution, resection rates, rates of chemotherapy performed, and histopathological distribution, etc. are detailed according to each cancer’s specificity. 　For instance, analysis of resection and stage are fattened out in regard to gastric cancer, colorectal cancer, lung cancer and breast cancer. As for malignant lymphoma, and leukemia, etc., histopathological distribution is mentioned in detail. 　The number of patients is estimated up to 2020 in this book. Future projections and analysis are conducted on major 19 types and the other types of cancers, and ultimately, the number of patients for 88 types (88 sites) malignant neoplasm under ICD-10 of Vital Statistics are calculated in this book. In the end, the total number of surviving patients was revealed.
Method of Usage
	Elucidation of the scale of the market for all 88 types of cancer (88 body sites) makes it possible to design fine-tuned market strategies for products on sale including new medicines. It is now possible to predict both the scale of markets focused on elements such as carcinomas, stages and histopathology and markets up to the year 2020. In other words, sales strategies can be thoroughly reviewed. 　Moreover, this enables companies to revise their thinking regarding whether they should sell new medicines or existing products themselves, or outsource sales to other companies from the perspective of the market scale (total number of surviving patients). Needless to say, this will also facilitate the adoption of concrete numerical targets for each product such as maximum sale volumes or target profit level settings. 　In addition, the ability to judge the market scale (total number of surviving patients) will also be of inestimable value for products such as medical devices and test drugs.